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The interleukin-17 (IL-17) family of cytokines has
emerged as a critical player in inflammatory diseases.
Among them, IL-25 has been shown to be important
in allergic inflammation and protection against
parasitic infection. Here we have demonstrated that
IL-17B, a poorly understood cytokine, functions to
inhibit IL-25-driven inflammation. IL-17B and IL-25,
both binding to the interleukin-17 receptor B (IL-
17RB), were upregulated in their expression after
acute colonic inflammation. Individual inhibition of
these cytokines revealed opposing functions in colon
inflammation: IL-25 was pathogenic but IL-17B was
protective. Similarly opposing phenotypes were
observed in Citrobacter rodentium infection and
allergic asthma. Moreover, IL-25 was found to pro-
mote IL-6 production from colon epithelial cells,
which was inhibited by IL-17B. Therefore, our data
demonstrate that IL-17B is an anti-inflammatory cyto-
kine in the IL-17 family.INTRODUCTION
Members of the interleukin-17 (IL-17) family of cytokines have
recently emerged as critical players in inflammation. IL-17A
and IL-17F are predominately expressed by CD4+ T helper 17
(Th17) cells, but can be produced by other lymphocytes as
well (Dong, 2008; Cupedo et al., 2009; Takatori et al., 2009; Rey-
nolds et al., 2010; Sawa et al., 2010). Recently, IL-17C and its
receptor IL-17 receptor E (IL-17RE) have been described to
regulate Th17 cell responses and epithelial cell-dependent colon
immunity (Chang et al., 2011; Ramirez-Carrozzi et al., 2011;
Song et al., 2011; Reynolds et al., 2012). IL-25 (IL-17E) is unique
in that it induces T helper 2 (Th2) cell-mediated inflammation
(Fort et al., 2001; Angkasekwinai et al., 2007; Zaph et al.,692 Immunity 42, 692–703, April 21, 2015 ª2015 Elsevier Inc.2008). IL-25 thus is protective against parasitic infection and is
produced by multiple cell types (Fallon et al., 2006; Owyang
et al., 2006; Moro et al., 2010; Neill et al., 2010; Price et al.,
2010; Saenz et al., 2010). IL-25 signals through a heterodimeric
receptor comprised of IL-17 receptor A (IL-17RA) and IL-17 re-
ceptor B (IL-17RB), both of which are necessary for IL-25 to pro-
mote cytokine production from target cells (Rickel et al., 2008;
Angkasekwinai et al., 2010). Outside of parasitic infection,
much less is known about the roles of IL-25 in the colon. Injection
of IL-25 throughout the course of DSS-induced colitis results
in a protective response; mice exhibit less inflammation and
increased survival (Mchenga et al., 2008). Conversely, in a model
of oxazolone-induced colitis, neutralizing IL-25 or IL-17RB can
decrease colonic inflammation (Camelo et al., 2012). Finally,
commensal flora drives the expression of IL-25 in the colon,
which might serve to limit the numbers of Th17 cells and IL-22-
expressing RORgt+ group 3 innate lymphoid cells (Zaph et al.,
2008; Sawa et al., 2011).
Little is known about IL-17B. The initial cloning and character-
ization reveals that human IL-17B can induce tumor necrosis
factor a (TNF-a) and IL-1b production by THP-1 cells (Li et al.,
2000). Moreover, IL-17B is substantially expressed in the paws
of arthritic mice and polyclonal anti-IL-17B treatment amelio-
rates collagen-induced arthritis (Yamaguchi et al., 2007). Indeed,
mice injected with IL-17B exhibit a neutrophilia phenotype
similar to those injected with IL-17A (Schwarzenberger et al.,
1998; Shi et al., 2000). However, IL-17B and IL-25 share a
common receptor, IL-17RB (Shi et al., 2000; Huang et al.,
2014), suggesting that there might be unexplored and unique
functions of IL-17B, although the affinity of IL-17B for IL-17RB
is weaker compared to IL-25 (Lee et al., 2001). Non-immune
functions have been attributed to IL-17B as well, including roles
in development (You et al., 2005), fracture (Kokubu et al., 2008),
and cancer (Sanders et al., 2010; Huang et al., 2014).
Given that IL-17RB is expressed by mucosal epithelial cells
(Shi et al., 2000; Lee et al., 2001; Zhao et al., 2010), we have
investigated the potential role of IL-17B and IL-25 in the regula-
tion of mucosal inflammation. Opposing disease phenotypes by
IL-17B- and IL-25-deficient animals were observed in models of
Figure 1. Colon Epithelial Cells Produce IL-17B and IL-25 in Acute Colitis
(A) Colon samples were derived from healthy controls or from animals after 8 day DSS-induced colitis (left). DSS samples were further processed and separated
into leukocyte (CD45+) and epithelial cell (CD45) fractions (right). The relative expression of Il17b and Il25 was then measured by qPCR. n = 5 mice per group.
(B) Primary colon epithelial cells derived from healthy mice were activated through TLR (LPS, Pam3CSK4) and NOD2 (MDP) pathways for 6 hr. Il17b and Il25
mRNA expression was assessed by real-time RT-PCR.
(C) Total colon tissue was isolated from healthy WT and NOD2-deficient animals and then assessed for Il17b and Il25 expression by qPCR. n = 5 mice per group.
(D) C57BL/6 animals were left untreated (WT) or administered an antibiotic regiment (ABX) for 4 weeks to depletemicrobiota. Total colon tissue was then obtained
and the expression of Il17b and Il25 was measured by qPCR. n = 18 mice per group.
All gene values were normalized to the expression of the housekeeping gene Actb. Data are presented as mean + SD error bars and are representative of at least
three independent experiments. Student’s t test, *p < 0.05. See also Figure S1.acute colitis, airway inflammation, and Citrobacter rodentium
infection. Overall, our studies have identified a critical inhibitory
function for IL-17B in IL-25-mediated mucosal inflammation.
RESULTS
IL-17B and IL-25 Are Expressed byColonEpithelial Cells
To determine the function of IL-17B and IL-25 in colon inflamma-
tion, we first examined mRNA expression of Il17b and Il25 in
total colon tissues isolated from healthy C57BL/6 mice (WT) aswell as WT mice administered DSS for 8 days (Figure 1A). We
found that there was basal expression of both cytokines in
the colon under steady-state conditions. However, induction of
acute colitis by DSS led to a substantial increase in the expres-
sion of Il17b (10-fold) and Il25 (35-fold) mRNA (Figure 1A) as
well as protein (Figure S1). Given that multiple tissues have been
shown to express both cytokines (Li et al., 2000; Shi et al., 2000;
Lee et al., 2001; You et al., 2005; Sanders et al., 2010), we next
examined the contribution of hematopoietic and non-hemato-
poietic cells in the production of each. We first isolated colonsImmunity 42, 692–703, April 21, 2015 ª2015 Elsevier Inc. 693
from DSS-induced WT animals and then separated cells on the
basis of CD45 and CD16/32 expression. We found that the
majority of Il17b and Il25 mRNA expression was clearly in the
colon epithelial cell (CEC) (CD45CD16/32) fraction (Figure 1A),
which is consistent with our previous report that epithelial cells
are a major source of IL-25 (Angkasekwinai et al., 2007).
The increased expression of IL-17B and IL-25 during colitis
led us to investigate which signal(s) regulated expression.
In vitro stimulation of CECs with toll-like receptor-4 (TLR4)
agonist (LPS) and TLR1 and 2 agonist (Pam3CSK4) led to a
dose-dependent mRNA increase of both cytokine genes (Fig-
ure 1B). We also stimulated CECs with muramyl dipeptide
(MDP) and saw a similar enhancement of Il17b and Il25 expres-
sion (Figure 1B), suggesting that the nucleotide oligomerization
domain-2 (NOD2) pathway is important for the expression of
both by CECs as well. Indeed, deficiency in NOD2 led to reduced
basal Il17b and Il25 expression in healthy colons compared to
WT controls (Figure 1C).
Because IL-17B and IL-25were both expressed in colons from
healthy animals, we thought that expression might be regulated
by the microbiota. To investigate this hypothesis, we depleted
the gut microbiota via a broad antibiotic regiment (Ivanov et al.,
2008). Similar to a previous report (Sawa et al., 2011), we found
that antibiotic depletion of WT animals led to a substantial
decrease of Il25 expression in the colon (Figure 1D). Surprisingly,
antibiotic depletion only moderately reduced Il17b, suggesting
that the signals governing IL-17B production aremore restricted.
Deficiency in IL-25 Confers Protection against DSS-
Induced Colitis
We next testedWT and IL-25-deficient (Il25/) mice (Angkasek-
winai et al., 2010) for the development of colon inflammation
8 days after DSS administration. Both groups started to lose
weight 5 days after treatment, but Il25/ mice exhibited
considerable protection from the wasting disease manifesting
in WT controls (Figure 2A). Further analysis after euthanasia re-
vealed that themoderate weight loss observed in Il25/ animals
was directly attributable to decreased colonic inflammation;
characteristic inflammatory parameters such as colon length
and H&E histology revealed that Il25/ mice were protected
from inflammatory destruction, tissue remodeling, and leukocyte
infiltration typical of this mouse model (Figures 2B–2D).
After establishing the pathogenic function of IL-25 in colonic
inflammation, we next hypothesized that this phenotype is
driven by the action of CECs (Figure 1A). Therefore, we gener-
ated a mouse strain with epithelial-specific deletion of IL-25 by
crossing mice with floxed Il25 to mice with a cre recombinase
under control of the villin 1 promoter (Vil1-cre). The resulting
epithelial cell-specific conditional Il25/ mice (Il25fl/fl 3 Vil1-
cre) were then subjected to DSS-induced colitis. As expected,
Il25fl/fl 3 Vil1-cre animals exhibited resistance to DSS-induced
weight loss and colon shortening compared to WT controls (Fig-
ures 2E and 2F). Importantly, the expression of Il25 in the colons
derived from Il25fl/fl 3 Vil1-cre animals after DSS treatment was
4% of the expression found in co-housed WT littermates,
further demonstrating the importance of IL-25 expression by
CECs (Figure 2G). Similar to Il25/ animals, colon tissue was
less inflamed in Il25fl/fl3 Vil1-cremice compared to WT (Figures
2H and 2I).694 Immunity 42, 692–703, April 21, 2015 ª2015 Elsevier Inc.We next asked whether IL-25 regulates inflammation through
the production of pro-inflammatory mediators after the induction
of colitis. Indeed, colons isolated from Il25/ mice after DSS
administration were markedly reduced in mRNA and protein
expression of the IL-1b, IL-6, and TNF-a cytokines and the
CCL2 chemokine (Figure 2J). Thus, our results indicate that
IL-25, whose expression in epithelial cells is enhanced in DSS
colitis, plays a pathogenic role by regulating pro-inflammatory
mediators.
Defective IL-17B Expression Exacerbates the
Development of Acute Colitis
To examine the role of IL-17B in colon inflammation, we gener-
ated a mouse strain containing a genetrap in the upstream pro-
moter of Il17b (IL-17B-deficient). This strain develops normally
and exhibits substantially reduced Il17b mRNA and protein
expression in mucosal tissues (Figure S2). Next we performed
DSS-induced colitis in these animals. Surprisingly, defective
IL-17B led to an opposing phenotype compared to Il25
deletion (Figure 2). IL-17B-deficient mice began to lose weight
earlier than their WT counterparts (Figure 3A) and colons were
consistently shorter (Figure 3B). Moreover, H&E analysis re-
vealed greater leukocyte infiltration, thickening, and goblet
cell destruction as a result of IL-17B deficiency (Figures 3C
and 3D). To determine the basis for these observations,
we next isolated mRNA and protein from colons of WT and
IL-17B-deficient mice (Figure 3E). In contrast to our observa-
tions in Il25/ animals (Figure 2), we observed that inflamma-
tory mRNA and protein (IL-1b, IL-6, TNF-a, and CCL2) was
markedly increased in animals lacking IL-17B. Overall, these
results suggest that although both IL-25 and IL-17B bind to
IL-17RB, they differentially regulate the development of colonic
inflammation.
IL-17B Inhibits IL-25-Induced IL-6 Production
To further investigate the mechanisms underlying the opposing
phenotypes in these animals, we first examined the contribution
of IL-17RB signaling. Bone marrow chimeras were generated
with IL-17RB present and/or absent (Watarai et al., 2012)
in the hematopoietic and non-hematopoietic compartments.
Mice deficient in IL-17RB in both compartments exhibited resis-
tance to DSS, similar to Il25/ mice (Figure 4A). Conversely,
mice with IL-17RB deficiency only in leukocytes exhibited weight
loss consistent withWT. Finally, animals with deletion of IL-17RB
in the non-immune cells exhibited protection from DSS colitis
(Figure 4A). Thus, CECs are not just the primary source of
IL-25 (Figure 2), but are probably the primary cells responding
to IL-25 in this model.
To investigate how IL-17RB promotes colonic inflammation,
we next examined the effect of IL-25 on the production of IL-6
by CECs. We focused on IL-6 production because of the corre-
lation of expression with disease severity (Figures 2J and 3E) and
its importance in colon inflammation and cancer (Atreya et al.,
2000; Gay et al., 2006; Yen et al., 2006; Tajima et al., 2008; Gri-
vennikov et al., 2009). When treating either the young adult
mouse colon (YAMC) cell line or primary CECs with IL-25, we
observed a dose-dependent effect of inducing IL-6 production
(Figure 4B). In contrast, IL-17B had no effect in promoting IL-6
or other mRNAs from YAMCs or CECs (Figure S3A). Because
Figure 2. IL-25-Deficient Mice Are Protected from DSS-Induced Colitis
(A) Acute colitis was induced in WT and Il25/mice by the addition of DSS in drinking water (n = 5–6 per group). Weight loss during colitis progression is shown.
(B) Mice with colitis were euthanized on day 8, colon length was measured from individual mice, and data were combined.
(C) Representative H&E histology from intermediate colon sections derived from the mice in (A).
(D) Combined histological scores of all mice and all sections (proximal, intermediate, and distal) in (A).
(E) Weight loss of WT and Il25fl/fl 3 Vil1-cre mice throughout the course of DSS-induced colitis. n = 5–6 mice per group.
(F) Combined individual colon lengths from the mice in (E).
(G) Combined expression of total colon Il25 mRNA from each mouse in (E).
(H) Representative H&E histology from middle colon sections from mice in (E).
(I) Combined histological scores from all colon sections of DSS mice presented in (E).
(J) Total colon tissue was isolated frommice 8 days after the induction of DSS colitis and equivalent biopsy sections were taken for inflammatory mRNA analysis
(qPCR) or were cultured in media overnight for cytokine analysis in supernatants (ELISA).
The data from individual mice were combined for each group. All gene values were normalized to the expression of Actb. Data from individual mice are presented
as mean + SD error bars and are representative of at least three independent experiments. Student’s t test, *p < 0.05 for comparisons between WT control and
Il25/ groups.IL-25 induced IL-6, we next asked whether this effect was
dependent on the IL-17RA and IL-17RB heterodimer as well as
the Act1 adaptor, all of which are known to be required for
IL-17RB signaling in other cells (Chang et al., 2006; Qian et al.,
2007; Rickel et al., 2008; Claudio et al., 2009; Angkasekwinai
et al., 2010). Stimulation of IL-17RA- (data not shown),
IL-17RB- (Figure 4C), or Act1 (Traf3ip2)-deficient (Figure 4D)CECs with IL-25 resulted in little to no IL-6, indicating that
IL-25 signaling in CECs is comparable to other cell types.
Although we could not observe a discernible effect of IL-17B,
we investigated whether IL-17B influences IL-25-mediated IL-6
expression, considering the opposing colitis phenotypes (Fig-
ures 2 and 3). We isolated primary CECs and stimulated them
with a fixed concentration of IL-25 (200 ng/ml) accompaniedImmunity 42, 692–703, April 21, 2015 ª2015 Elsevier Inc. 695
Figure 3. IL-17B-Deficient Mice Exhibit
Exacerbated Colitis
(A) Weight loss (percent of starting weight) was
assessed daily in WT and IL-17B-deficient mice
after DSS administration. n = 5–6 mice per group.
(B) Colons were isolated from individual mice
after sacrifice at day 8 and then measured and
combined for each group.
(C and D) Colon tissue derived from the mice in (A)
were sectioned and then stained with H&E (C)
to measure infiltration and inflammation (D) in
individual mice after DSS onset at day 8.
(E) Total colon tissue was divided into similar
sections and then combined for each mouse.
mRNA was then isolated and gene values were
measured by qPCR with the expression of Actb as
a reference. Supernatants from the colonwere also
assayed for cytokine expression by ELISA.
Data are presented as mean + SD error bars and
are representative of at least three independent
experiments. Student’s t test; *p < 0.05 in com-
parison of IL-17B-deficient to WT controls. See
also Figure S2.by simultaneous treatment of increasing IL-17B. We found that
IL-17B treatment resulted in a reduction of IL-6 (Figure 4E).
High-dose IL-17B almost completely abolished IL-6 mRNA and
protein, suggesting that IL-17B might restrict IL-25 signaling.
Conversely, IL-17B could not inhibit IL-6 expression induced
by IL-17 (Figure S3B). These results suggest that IL-17B inhibits
IL-25 binding to IL-17RB as a means to dampen IL-25 signaling.
Therefore, we analyzed the binding of IL-25-hIg to IL-17RB or IL-
17RB and IL-17RA in the presence of increasing IL-17B (Figures
4F and S3C). Low-dose IL-17B was unable to inhibit IL-25 bind-
ing to HEK293 cells expressing IL-17RB alone. However, high
doses of IL-17B substantially inhibited binding. Moreover,
when cells expressed both IL-17RB and IL-17RA, IL-17B could
inhibit IL-25 binding at lower concentrations. These data suggest
that IL-25 binds to IL-17RB regardless of IL-17RA, though dimer-
ization of IL-17RB to IL-17RA is critical for the transmission
of signal (Figures 4B–4D). IL-17B preferentially inhibited IL-25
binding to the heterodimeric form of the receptor (Figure 4F).
However, IL-17A had no effect on IL-25 binding to IL-17RB or
the IL-17RB and IL-17RA complex.
Because IL-17B deficiency led to greater colitis severity, we
asked whether treatment of WT or IL-17B-deficient mice with696 Immunity 42, 692–703, April 21, 2015 ª2015 Elsevier Inc.IL-17B could improve disease severity.
We found that treatment of mice by i.p.
IL-17B injection at the start of DSS was
sufficient to improve weight loss (Fig-
ure S3D) in WT animals. Furthermore,
IL-17B treatment in IL-17B-deficient ani-
mals led to a partial rescue from wasting
disease.
To test whether the severe DSS pheno-
type in IL-17B-deficientmice exaggerated
IL-25 signaling, we crossed IL-25- and
IL-17B-deficient mice to create double-
deficient mice (IL-17B-deficient, Il25/).
We treated these mice with DSS andfound that additional IL-25 deletion greatly improved wasting in
IL-17B-deficient animals (Figure 4G). Moreover, colonic inflam-
mation was identical in the WT and IL-17B-deficient, Il25/
animals (Figure 4H) as was Il6 mRNA expression in the colon
(Figure 4I). Thus, the deficiency of both IL-17B and IL-25 reverts
a single-deficient animal back to the WT phenotype.
Opposing Roles of IL-17B and IL-25 in Response to
C. rodentium
To determine whether IL-17B and IL-25 functions are specific
to acute colitis or further manifest in general inflammatory
responses, we orally infected WT, IL-17B-deficient, and Il25/
mice withCitrobacter rodentium, a murine-specific, Gram-nega-
tive model for human E. coli infection (Luperchio and Schauer,
2001). All experiments were performed on mice co-housed or
on a rotating cage system to minimize differential microbiota
effects (Elinav et al., 2011). IL-17B-deficient mice consistently
exhibited amild, but significant, weight loss compared toWT an-
imals (Figure 5A). This weight loss correlated with an extensive
bacterial burden in the feces, indicating a failure to properly
control the pathogen (Figure 5B). The bacterial load in the liver
and spleen, an indicator of dissemination, was also higher with
Figure 4. IL-17B Inhibits IL-25-Mediated
IL-6 Production in Colon Epithelial Cells
(A) Bone marrow chimeric mice were generated
with WT and Il17rb/ animals as donors and re-
cipients. The first genotype designation in the
legend identifies hematopoietic cell origin (WT: or
Il17rb/:) and the second represents non-he-
matopoietic cell origin (:WT or :Il17rb/).
(B) IL-6 expression was measured by qPCR after
6 hr stimulation with recombinant IL-25 in a colon
epithelial cell line (YAMC) and primary colon
epithelial cells (CECs).
(C and D) IL-6 mRNA expression was similarly
measured from CECs derived from IL-17RB-defi-
cient (C) and Act1 (Traf3ip2/)-deficient (D) mice.
(E) IL-6 was examined in CECs after fixed IL-25
stimulation (200 ng/ml) followed by simultaneous
treatment of increasing IL-17B concentrations.
IL-6 was measured by qPCR (6 hr stimulation, top)
and ELISA (24 hr stimulation, bottom).
(F) Summary of competition experimentsmeasuring
the ability of increasing concentrations of IL-17B
or IL-17A to displace IL-25-hIg bound to murine
IL-17RB (RB) or IL-17RB and IL-17RA (RB+RA).
Competition (%) is the percentage of IL-25
displacement at each IL-17B or IL-17A concentra-
tion compared those treated with only IL-25.
(G) Combined weight loss data from WT, IL-17B-
deficient, and IL-17B and IL-17E double-deficient
(IL-17B-deficient, Il25/) mice after DSS admin-
istration. n = 7–8 mice per group.
(H) Representative H&E histology and combined
histological scores of all colon sections from the
mice shown in (G).
(I) Combined IL-6 mRNA expression from total
colon samples derived from the mice in (G).
Data are presented as mean + SD error bars and
are representative of two independent experi-
ments (A) and at least three independent experi-
ments in (B)–(I). mRNA data were obtained by
examining relative gene expression to Actb. Stu-
dent’s t test; *p < 0.05 for daily comparisons of
WT:WT mice to Il17rb/:Il17rb/ mice and **p <
0.05 for daily comparisons of WT:Il17rb/mice to
Il17rb/:Il17rb/ mice (A); *p < 0.05 for daily
comparisons of IL-17B-deficient to IL-17B-defi-
cient, Il25/ mice (G); **p < 0.05 for comparison
of IL-17B-deficient to WT and IL-17B-deficient,
Il25/ mice (I). See also Figure S3.IL-17B deficiency; however, only a modest count was obtained
from these organs, possibly due to the relatively low CFU for
infection (Figure S4A). Thus, IL-17B deficiency is pathogenic
for Citrobacter rodentium infection, similar to DSS-induced
colitis, although the mechanism probably is different due to the
importance of IL-6 in combatingC. rodentium (Dann et al., 2008).
We next performed similar experiments with Il25/mice. For
reasons unknown, in these experiments WT animals had aImmunity 42, 692–moderate weight loss (Figure 5C). None-
theless, Il25/ mice did exhibit a slight,
but significant, improvement in weight
compared to WT mice (Figure 5C),
indicating that IL-25 is important forC. rodentium defense. Further analysis revealed a similar trend
where fecal bacteria were significantly reduced in Il25/ mice
(Figure 5D). The protective effect observed in Il25/ mice,
however, did not reach the threshold for statistical significance
for spleen and liver comparisons (Figure S4A).
IL-22 is critical cytokine for combating Citrobacter infection
(Zheng et al., 2008). Therefore, we analyzed Il22 mRNA and
protein in infected colons (Figure S4B). We found that IL-22703, April 21, 2015 ª2015 Elsevier Inc. 697
Figure 5. IL-17B Is Protective against Citro-
bacter rodentium Infection
(A, C, E) WT and IL-17B-deficient (A), WT and
Il25/ (C), or WT and IL-17B-deficient, Il25/ (E)
mice were orally infected with 2 3 109 CFUs of
Citrobacter rodentium and weighed daily for 12–
13 days. n = 7–18 mice per group.
(B, D, F) After harvest, feces were collected, ho-
mogenized, and then examined for Citrobacter
rodentium growth on MacConkey agar after
overnight incubation.
Data are presented as mean + SD error bars and
are representative of at least three independent
experiments. Student’s t test; *p < 0.05. See also
Figure S4.expression was decreased in Il25/ mice and increased in IL-
17B-deficient mice, which was somewhat surprising considering
that IL-17B-deficient mice were susceptible and Il25/ mice
were protected againstCitrobacter infection. Thus, the functions
of IL-25 and IL-17B in the innate response to pathogens are
complex and likely to involve other factors outside of IL-6 and
IL-22. When analyzing IL-17B-deficient, Il25/ animals, we
found that deletion of both cytokines during infection resulted
in a phenotype equivalent to WT animals, including weight
loss, bacteria load, and IL-22 production (Figures 5E, 5F, S4A,
and S4B), similar to that observed in DSS experiments (Figures
4G–4I).
Opposing Functions of IL-17B and IL-25 in Airway
Inflammation
Previous work has demonstrated that IL-25 mediates allergic
inflammation by promoting Th2 cell responses and facilitating
eosinophil recruitment (Fort et al., 2001; Angkasekwinai et al.,
2007, 2010). Consequently, animals lacking IL-25 are protected
against the development of experimental asthma. In allergic
asthma induced by OVA and alum, IL-17B is also induced in the
lung tissue (Figure S5A). Although lack of IL-25 led to a reduction
of eosinophils in this model, the bronchoalveolar lavage fluid
(BALF) of IL-17B-deficientmicewasmarkedby substantial eosin-698 Immunity 42, 692–703, April 21, 2015 ª2015 Elsevier Inc.ophil influx (Figure6A).Whenweexamined
various Th2 cell mediators, we expectedly
found that the IL-4, IL-5, and IL-13 cyto-
kines were reduced in Il25/ and exacer-
bated in IL-17B-deficientmice (Figure 6B).
A similar profile was obtained when
analyzing the total lung mRNA (Figure 6C).
IL-9, regulated by IL-25 (Angkasekwinai
et al., 2010), was increased in the lungs
of IL-17B-deficient animals as well (Fig-
ure 6C). Similarly, the BALF of Il25/
mice exhibited a loss of the Th2 cell
compartment upon OVA restimulation
whereas IL-17B-deficient BALF contained
increasednumbersofTh2cells (Figure6D).
To further examine Th2-cell-mediated re-
sponses, we restimulated total splenic
and mediastinal lymph node cells with
OVA for 3 days and analyzed cytokineproduction.We foundasimilar exacerbationof Th2cell responses
in the cells isolated from IL-17B-deficient mice (Figure 6E). Thus,
IL-25 strongly promotes allergic airway inflammation through
enhanced Th2 cell responses whereas IL-17B conversely re-
strains Th2 cell responses in the airway.
To determine the outcome of deleting both cytokines in this
model, we performed a similar set of experiments in IL-17B-defi-
cient, Il25/mice (Figures S5B–S5D). We found that respiratory
infiltration as well as Th2 cell cytokine production was equivalent
betweenWT and IL-17B-deficient, Il25/ animals. These results
indicated that removal of both cytokines counteracts the pheno-
types observed in single-deficient mice, similar to what was
observed for DSS (Figure 4) and Citrobacter rodentium infection
(Figure 5).
DISCUSSION
The pro-inflammatory functions of IL-17 have been well docu-
mented (Dong, 2008). Here, we have demonstrated further func-
tional complexity among the IL-17 family of cytokines. Adding to
a well-established role in type 2 immunity, we found that IL-25
was pathogenic in acute colitis, whereas IL-17B was conversely
protective. These opposing effects were similar in Citrobacter
rodentium infection and allergic asthma. Notably, we have found
Figure 6. IL-17B and IL-25 Have Opposing Roles during Allergic Asthma
(A) Total cell counts in the BAL fluid of WT, IL-17B-deficient, and IL-25-deficient animals sensitized with OVA in alum at day 0 and 14, followed by intranasal
challenge with OVA at days 14, 25, and 26.
(B) BALF derived from the animals in (A) was assayed for the presence of IL-4, IL-5, and IL-13 by ELISA.
(C) Combined mRNA analysis of Th2 and Th9 cell-associated genes from total lung samples derived from the mice in (A).
(D) Representative (left) and combined analysis (right) of Th2 cell frequencies in the BALF of OVA and alum sensitized animals. T cells isolated from the BALFwere
restimulated with 50 mg/ml OVA prior to intracellular cytokine staining for IL-4 and IL-5.
(E) Analysis of splenic and mediastinal lymph node Th2 cell compartments after 3 days restimulation with increasing doses of OVA. IL-4, IL-5, and IL-13 protein
was measured from the supernatants by ELISA.
Data are presented as mean of data obtained from individual mice + SD error bars and are representative of at least three independent experiments. Student’s
t test; *p < 0.05 for comparisons of WT to IL-17B-deficient and **p < 0.05 for comparisons of WT to Il25/. See also Figure S5.a unique role for IL-17B in inhibiting IL-25-mediated IL-6 produc-
tion by CECs, making IL-17B an antagonistic and anti-inflamma-
tory cytokine in this family.
IL-25 is generally thought of as a Th2-cell-derived factor, pro-
moting allergic asthma responses but also protecting against
parasitic infection (Reynolds et al., 2010). Here, we have shown
that IL-25 in acute colitis promoted IL-6 production from CECs,
which is consistent with a report of IL-25 promoting the release
of IL-6 from eosinophils (Wong et al., 2005). Throughout the
course of this study, IL-25-dependent IL-6 production was the
most consistently inhibited by IL-17B treatment. However, at
this time we cannot rule out the influence of other mediators in
promoting the protective and pathogenic phenotypes observed
in IL-25- and IL-17B-deficient mice, respectively. Most likely,
IL-17B antagonism of IL-25 is influencing multiple facets of themucosal immune response, which is the subject of our current
investigations.
Our finding that IL-25 deletion protects against DSS differs
from another showing that injecting IL-25 protects against the
development of DSS colitis (Mchenga et al., 2008). Though we
cannot fully explain the discrepancy between reports, IL-25
stimulation of primary CECs in vitro promoted the production
of IL-6, consistent with decreased inflammation observed in
Il25/ mice. Indeed, when we injected WT mice directly with
IL-25 (not shown) or IL-17B, we observed phenotypes opposite
to those found in cytokine-deficientmice. Thus, different housing
conditions or microbiota might influence results obtained from
recombinant protein injection.
IL-17B has long been a mysterious member of the IL-17 cyto-
kine family. Previous work has demonstrated that IL-17RBmightImmunity 42, 692–703, April 21, 2015 ª2015 Elsevier Inc. 699
be oncogenic whereas IL-17B might contribute to tumor cell
growth (Tian et al., 2000; Furuta et al., 2011; Huang et al.,
2014). The original report characterizing IL-17B demonstrates
that this cytokine stimulates the release of TNF-a and IL-1b
from THP-1 cells. However, we did not observe production of
pro-inflammatory mediators after IL-17B stimulation, consistent
with IL-17B being unable to induce IL-6 from fibroblasts (Li et al.,
2000). Instead, the primary effect we observed for IL-17B treat-
ment in CECs was direct inhibition of IL-25-mediated IL-6
production. This of course begs the question of how exactly
IL-17B can inhibit IL-25-mediated IL-6 production in CECs.
One possibility is that IL-17B competes with IL-25 for binding
IL-17RB. Indeed, we found that IL-17B inhibited IL-25 binding
to IL-17RB or IL-17RA and IL-17RB complexes. Because
previous work has demonstrated that IL-17A and IL-17F form
heterodimers, we investigated this possibility as well. However,
exhaustive attempts to identify IL-17B and IL-25 heterodimers
were unsuccessful (not shown), suggesting that competition
for IL-17RB binding causes functional antagonism. IL-17B had
higher activity in blocking IL-25 binding to the IL-17RA and IL-
17RB heterodimer compared to IL-17RB alone. Conversely, IL-
25 was capable of binding IL-17RB in the absence of IL-17RA,
suggesting that IL-17RAwasmore important for signaling. These
binding assays have limitations considering that we cannot rule
out the contribution of endogenous IL-17 receptors that might
be expressed in the human HEK cells, because we do not
know whether the murine IL-17RB could form heterodimers
with endogenous human IL-17RA. Another caveat is that only
mouse receptors were co-expressed in these cells and more
direct studies need to be performed in the future on both mouse
and human IL-17RA and IL-17RB similar to studies on IL-17 and
IL-17F (Toy et al., 2006; Kuestner et al., 2007). Finally, we need
to determine whether IL-17RB is internalized after binding of
IL-17B, IL-25, or both. Differential IL-17RB internalization could
represent another mechanism governing IL-17B regulation of
IL-25.
Our current model is that colon inflammation enhances IL-25
pro-inflammatory signaling while IL-17B is concurrently induced
to restrain IL-25. IL-25 has a higher affinity for IL-17RB
alone compared to IL-17B. However, treatment with IL-17B
throughout the course of DSS colitis led to protection in WT
animals, indicating that a shift in the IL-25 to IL-17B ratio can
influence the course of inflammation. Previous work has demon-
strated that IL-17F in some situations antagonizes IL-17
signaling, including forming heterodimeric complexes with IL-
17 that have weaker activity compared to IL-17 alone (Wright
et al., 2008). We believe that the antagonism exerted on IL-25
signaling by IL-17B, however, is unique to this family because
IL-17F by itself can activate signaling pathways important for
inflammation (Yang et al., 2008) but we have yet to find a stand-
alone function for IL-17B. Moreover, IL-17B could not antago-
nize IL-6 production induced by IL-17 in CECs, demonstrating
the specificity of IL-17B action. Therefore, further study is
needed to determine whether IL-17B alone can transmit a func-
tional signal to any cell type and to determine the precise mech-
anism for how IL-17B is inhibiting IL-25 binding to IL-17RB.
The prospect of modulating IL-17RB signaling for the treat-
ment of colitis at this time seems promising. Our findings that
recombinant IL-17B injections throughout the course of DSS700 Immunity 42, 692–703, April 21, 2015 ª2015 Elsevier Inc.administration can improve disease outcome in WT animals
further supports this theory. Whether IL-17B is as important in
human IBD is currently under investigation. The production of
IL-25 has been linked to human IBD even though polymorphism
is not believed to be a risk factor (Bu¨ning et al., 2003). Two recent
reports have shown that inflammatory bowel disease (IBD) pa-
tients have decreases in IL-25 (Caruso et al., 2009; Su et al.,
2013). These results might suggest that IL-25 is a protective fac-
tor in human IBD; however, IL-17B expression in these patients
has yet to be determined. Decreased IL-25 expression in human
IBD might also be representative of a failure of IL-17B to control
inflammation. Thus, further investigation is necessary to deter-
mine the role of IL-17B in human IBD as well as determining
whether IL-17RB represents a viable therapeutic target.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice were purchased fromNCI, andNod2/ and Vil1-cremice were
purchased from The Jackson Laboratory. Il25fl/fl and IL-25-deficient mice have
been previously described (Angkasekwinai et al., 2010). Il25fl/fl mice were
crossed with Vil1-cre mice on the B6 background to generate Il25fl/fl 3 Vil1-
cre mice. IL-17B-deficient mice were generated by gene trapping in the R1
ES cell line (clone 371C12; Toronto Centre for Phenogenomics, Centre for
Modeling Human Disease). Both IL-25- and IL-17B-deficient mice have been
backcrossed to B6 background for >8 generations. Il17rb/ and Traf3ip2/
(Act1) mice have previously been described (Chang et al., 2011; Watarai et al.,
2012). All experiments were conducted on 6- to 12-week-old animals with
protocols approved by the Rosalind Franklin University of Medicine and
Science and MD Anderson Cancer Center Institutional Animal Care and Use
Committees. Additional information on experimental mice can be found in
the Supplemental Experimental Procedures.
Antibiotic Depletion of Commensal Flora
Commensal flora was depleted with a previously described regiment (Ivanov
et al., 2008). In brief, mice were administered water containing a cocktail of
ampicillin (Sigma-Aldrich), neomycin (Fisher Scientific), vancomycin (Fisher),
and metronidazole (Fisher) for 4 weeks.
DSS-Induced Colitis
All experiments were performed with 6- to 12-week-old mice on the C57BL/6
background that were fed DSS in drinking water at a concentration of 2%–
3.5% (w/v) for a total period of 5 days. Starting weights were recorded and
then mice were weighed and monitored daily until the experimental endpoint
(day 8). For analysis, total colon tissue was harvested from animals and colon
lengths were recorded. Colon sections were then divided into proximal, inter-
mediate, and distal sections for H&E histological analysis. Sections from each
region were also combined in plated in media overnight for supernatant
analysis of cytokines by ELISA. Sections were also combined and lysed in
TRIzol (Life Technologies) for analysis of mRNA expression by qPCR. Addi-
tional analysis methods, including mRNA, histology, and protein analysis,
can be found in the Supplemental Experimental Procedures.
Cell Lines and CECs
YAMC cells were a generous gift from Dr. Dingzhi Wang at the University of
TexasMDAnderson Cancer Center. The isolation of CECs has been described
previously (Reynolds et al., 2012). Primary CECs were plated and rested in 96-
well dishes prior to stimulation with LPS (Sigma-Aldrich), Pam3CSK4 (Invivo-
gen), MDP (Invivogen), or the indicated concentration of mouse IL-17B and/
or IL-25 (R&D Systems) for 6 hr (mRNA) or 24 hr (ELISA). Additional experi-
mental details can be found in the Supplemental Experimental Procedures.
Cytokine Binding
To analyze IL-25 binding to IL-17RB, a recombinant IL-25 tagged with human
Ig (IL-25-hIg) was raised in Drosophila S2 cells as described previously
(Angkasekwinai et al., 2007). In brief, HEK293T cells were retrovirally trans-
fected with constructs encoding murine Il17ra or Il17rb. After transfection,
the indicated concentrations of IL-17A, IL-17B (R&D Systems), or IL-25-hIg
were added simultaneously for 30 min followed by the determination
of IL-25-hIg surface binding by flow cytometery using anti-hIg conjugated
to APC. Additional details can be found in the Supplemental Experimental
Procedures.
Generation of Bone Marrow Chimeras
Recipient WT or Il17rb/ mice (6–8 weeks) were irradiated with 750 rad and
injected intravenously with 53 106 donor cells as indicated. After 6 weeks, re-
constituted mice were administered 3% DSS in drinking water as described
above.
Citrobacter rodentium Infection
C. rodentium (ATCC 51459) infection was performed with 2 3 109 CFU as
previously described (Hu et al., 2013). Mice were weighed for 13–14 days
after infection and colon mRNA and cytokine production was analyzed
as described above for DSS colitis. Bacterial load was assessed by plating
fecal, liver, or splenic homogenates overnight on MacConkey agar. Addi-
tional details for this model can be found in the Supplemental Experimental
Procedures.
OVA-Induced Asthma
Mice were immunized i.p. with 50 mg of grade VII OVA (Sigma) emulsified in
alum (Thermo) at days 0 and 14 followed by i.n. administration of 50 mg OVA
at days 14, 25, and 26 as described previously (Angkasekwinai et al., 2010).
In brief, at day 28, BALF was collected for IL-4, IL-5, and IL-13 determinations
by ELISA (BD Biosciences). BALF was also analyzed for leukocyte infiltration
via flow cytometry and Dif-Quick (Fisher) histological staining. Finally, lympho-
cytes isolated from the BALFwere restimulated with OVA to determine Th2 cell
generation by staining with antibodies specific for IL-4 and IL-5 (eBioscience).
Lung tissue was collected and homogenized in TRIzol for the determination of
cytokine gene expression by qPCR. Mediastinal lymph nodes and spleens
were collected from each mouse, homogenized, and then stimulated with
the indicated concentrations of OVA for 3 days. IL-4, IL-5, and IL-13 expres-
sion was then measured in the supernatants by ELISA.
Statistical Analysis
Statistical comparisons were performed by two-tail paired Student’s t test.
p values less than 0.05 were considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.immuni.2015.03.008.
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